November 4, 2025 — NeuroPace, Inc. (Nasdaq: NPCE) reported its third-quarter financial results and provided a corporate update. The company’s total revenue was $27.4 million, a 30% increase compared to the third quarter of 2024. RNS® System revenue was $22.6 million, representing a 31% increase.
The company also achieved record highs in the number of active accounts, prescribers, and utilization. NeuroPace completed a pre-submission meeting with the FDA for the NAUTILUS study, which evaluates RNS therapy in idiopathic generalized epilepsy (IGE). The company remains on track to submit a premarket approval supplement (PMA-S) by the end of 2025.
NeuroPace submitted Seizure ID™, the first of its planned NeuroPace AI™ applications, to the FDA for approval. This product is designed to improve clinical outcomes and streamline the iEEG review process, utilizing years of patient-level brain data from the RNS System.
Joel Becker, CEO of NeuroPace, highlighted the company’s strong third-quarter performance, attributing it to continued strategic execution and team momentum. The company has increased its total revenue guidance for full-year 2025 to between $97 million and $98 million.
NeuroPace will host a conference call to discuss these results on Tuesday, November 4, 2025, at 4:30 P.M. Eastern Time. Access details are available on the company’s investor relations website.
Contact:
https://investors.neuropace.com/news-and-events/events
+ 1 (800) 715-9871 and referencing Conference ID 8467256
Source: NeuroPace, Inc.
